Everolimus

10 mg

Cat. No.: 55-X21

$114.00

Everolimus inhibits mTOR (mammalian target of rapamycin), a serine-threonine kinase, by binding with high affinity to the FK506 binding protein-12 (FKBP-12) thus inducing cell growth arrest and apoptosis. It is chemically very similar to Rapamycin. It is also used to prevent rejection of organ transplants.

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: 40-O-(2-Hydroxyethylrapamycin)

Chemical Formula: C53H83NO14

CAS Number: 159351-69-6

Molecular Weight: 958.22

Purity: >99%

IC50= .63nM (mTOR)

Appearance: Off white solid powder

Solubility: DMSO (100mM)

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO. Soluble at 20mg/ml

References

Motzer | R.J. | et al (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind | randomized | placebo-controlled phase III trial. Lancet. 372:449-56.

Baselga | J. | et al (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520-9.

Yao | J.C. | et al (2011). Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 364:514-23.

Tech Docs

Product Specifications

MSDS

Related products